Publications
Across the nation, policymakers are beginning to recognize the importance of allowing innovative access to birth control for women. In recent years, 11 states plus the District of Columbia have…
Testimony from:
Courtney Joslin, Commercial Freedom Fellow, R Street Institute
Regarding SB 286, An Act to amend 450.095 (title) and 450.095 (3); and to create 450.01 (16) (L), 450.095 (1) (ag)…
Testimony from:
Lauren L. Rollins, Fellow and Editorial Director, R Street Institute
In SUPPORT of S. 1309, “AN ACT Relative to Hormonal Contraceptives”
September 10, 2019
Joint Committee on…
The United States has one of the highest unintended pregnancy rates in the world, along with some of the most restrictive contraceptive access laws. Its rates of unintended pregnancy are 16 percent…
Testimony from:
Caroline Kitchens, Director of Federal Affairs, R Street Institute
Regarding AB304, “An Act to amend 450.095 (title) and 450.095 (3); and to create 450.01 (16) (L), 450.095 (1)…
The pharmacy access model removes unnecessary regulations, provides women with more accessible healthcare options, and reduces public health expenditures. Expanding the scope of practice for…
This pharmacy access model expands birth control access in a way that saves time—pharmacists can prescribe and dispense the prescription—and sensibly increases the scope-of-practice that…
The Honorable Joseph J. Simons
Chairman, Federal Trade Commission
600 Pennsylvania Avenue, N.W.
Washington, D.C. 20530
Dear Chairman Simons:
The following comments are…
From National Journal:
Ernst and Gardner in separate interviews say they continue to advocate for the bill’s passage. Free-market advocates at the R Street Institute and other groups penned…